stoxline Quote Chart Rank Option Currency Glossary
  
Aclarion, Inc. (ACON)
0.23  -0.014 (-5.74%)    12-07 15:58
Open: 0.2423
High: 0.2455
Volume: 60,178
  
Pre. Close: 0.244
Low: 0.23
Market Cap: 2(M)
Technical analysis
2023-12-07 4:18:46 PM
Short term     
Mid term     
Targets 6-month :  0.35 1-year :  0.41
Resists First :  0.3 Second :  0.35
Pivot price 0.27
Supports First :  0.23 Second :  0.19
MAs MA(5) :  0.25 MA(20) :  0.28
MA(100) :  0.42 MA(250) :  0.61
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  3.9 D(3) :  7.9
RSI RSI(14): 34.4
52-week High :  2.36 Low :  0.23
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ACON ] has closed above bottom band by 10.9%. Bollinger Bands are 40.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.26 - 0.26 0.26 - 0.27
Low: 0.24 - 0.24 0.24 - 0.24
Close: 0.24 - 0.24 0.24 - 0.25
Company Description

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Headline News

Fri, 01 Dec 2023
BioNexus Gene Lab (NASDAQ:BGLC) vs. Aclarion (NASDAQ:ACON) Financial Comparison - Defense World

Mon, 27 Nov 2023
Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams - Yahoo Finance

Wed, 25 Oct 2023
Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring ... - OrthoSpineNews

Tue, 19 Sep 2023
Why Elutia Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket - Avinger (NASDAQ - Benzinga

Fri, 08 Sep 2023
Aclarion appeals latest Nasdaq delisting notice – BizWest - BizWest

Mon, 28 Aug 2023
Aclarion cuts losses but delayed report shows continued financial stress – BizWest - BizWest

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Health Information Services
Shares Out 0 (M)
Shares Float 9 (M)
Held by Insiders 5.89e+006 (%)
Held by Institutions 32.3 (%)
Shares Short 61 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -4.53e+006
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -6 %
Return on Assets (ttm) 95.8 %
Return on Equity (ttm) -104 %
Qtrly Rev. Growth 84130 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.6 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0
Stock Dividends
Dividend 0
Forward Dividend 35330
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android